Nils Olsson

Nils Olsson has extensive experience in the pharmaceutical industry, with a focus on regulatory affairs and CMC (Chemistry, Manufacturing, and Controls) functions. Nils'scareer began in 1980 at Fresenius Kabi, where they gained experience in GMP manufacturing. Nils then worked at various companies, including Karolinska Institutet and Karlshamns LipidTeknik AB, where they held roles related to quality control and analytical methods development. In 1994, they joined the National Institutes of Health as a post-doctoral fellow before transitioning to roles at Alliance Pharmaceutical Corp. and Elan Pharmaceuticals, where they focused on regulatory affairs for inhaled and solid drug products. From 2002 to 2013, Olsson served as the Vice President of Quality Control at Sangart, Inc., overseeing the manufacturing of large volume biologic parenteral drugs. Nils then joined Retrophin as Vice President of Chemistry, Manufacturing, and Controls, where they led global manufacturing strategy for a portfolio of small molecules, peptides, and biologics. Most recently, Olsson has been working at Gilead Sciences as the Director of Regulatory Affairs CMC, responsible for the regulatory strategy and life-cycle management of various pharmaceutical products. Currently, they hold the position of Vice President, CMC and Bioanalytical at Cerus, focusing on the development and life-cycle management of drug-device-biologics combination products.

Nils Olsson began their education at Stockholm University in 1982, where they pursued a Bachelor of Science degree in Chemistry. Nils successfully completed this program in 1987. Subsequently, Nils continued their studies at the same institution and obtained a Ph.D. in Analytical Chemistry, completing their doctoral program in 1991.